If point estimate for drug x for covid is 20% relative reduction in mortality, but 95% CI crosses 1, and we decline to prescribed. Then with more studies the CI tightens and point estimate doesn't change. Now clear it works 100 million patients not treated. 2/
Well, yes, but they supported the use and widespread application by using the argument that low quality evidence was good enough
-
-
Thats not low quality evidence, it's low benefit derived from high quality evidence.
-
That's what we've got now to rely on, but the initial evidence was very low quality and that was the justification for use. Their first trial had more authors than patients!
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.